These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23868005)

  • 1. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.
    Moreaux J; Reme T; Leonard W; Veyrune JL; Requirand G; Goldschmidt H; Hose D; Klein B
    Br J Cancer; 2013 Aug; 109(3):676-85. PubMed ID: 23868005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
    Aouali N; Broukou A; Bosseler M; Keunen O; Schlesser V; Janji B; Palissot V; Stordeur P; Berchem G
    PLoS One; 2015; 10(6):e0130339. PubMed ID: 26091518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
    Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
    Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.
    García-Guerrero E; Gogishvili T; Danhof S; Schreder M; Pallaud C; Pérez-Simón JA; Einsele H; Hudecek M
    Blood; 2017 Jun; 129(25):3386-3388. PubMed ID: 28476749
    [No Abstract]   [Full Text] [Related]  

  • 7. Genes are often sheltered from the global histone hyperacetylation induced by HDAC inhibitors.
    Halsall J; Gupta V; O'Neill LP; Turner BM; Nightingale KP
    PLoS One; 2012; 7(3):e33453. PubMed ID: 22479401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
    Cea M; Cagnetta A; Gobbi M; Patrone F; Richardson PG; Hideshima T; Anderson KC
    Curr Pharm Des; 2013; 19(4):734-44. PubMed ID: 23016853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni.
    Anderson L; Gomes MR; daSilva LF; Pereira ADSA; Mourão MM; Romier C; Pierce R; Verjovski-Almeida S
    PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005539. PubMed ID: 28406899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
    Mateen S; Raina K; Jain AK; Agarwal C; Chan D; Agarwal R
    Epigenetics; 2012 Oct; 7(10):1161-72. PubMed ID: 22965008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors.
    Fujii K; Suzuki N; Jimura N; Idogawa M; Kondo T; Iwatsuki K; Kanekura T
    J Dermatol Sci; 2018 Apr; 90(1):82-89. PubMed ID: 29395577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni.
    Dubois F; Caby S; Oger F; Cosseau C; Capron M; Grunau C; Dissous C; Pierce RJ
    Mol Biochem Parasitol; 2009 Nov; 168(1):7-15. PubMed ID: 19538992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
    Mazzio EA; Soliman KF
    Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.
    Bruyer A; Maes K; Herviou L; Kassambara A; Seckinger A; Cartron G; Rème T; Robert N; Requirand G; Boireau S; Müller-Tidow C; Veyrune JL; Vincent L; Bouhya S; Goldschmidt H; Vanderkerken K; Hose D; Klein B; De Bruyne E; Moreaux J
    Br J Cancer; 2018 Apr; 118(8):1062-1073. PubMed ID: 29500406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
    Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
    Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
    Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
    Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
    Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
    Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
    Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
    Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of histone deacetylase inhibitor and tumor cell-growth inhibition properties of new benzofuranone compounds.
    Blanquart C; François M; Charrier C; Bertrand P; Gregoire M
    Curr Cancer Drug Targets; 2011 Oct; 11(8):919-28. PubMed ID: 21762083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
    Chiba T; Yokosuka O; Fukai K; Kojima H; Tada M; Arai M; Imazeki F; Saisho H
    Oncology; 2004; 66(6):481-91. PubMed ID: 15452378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.